OS Therapies (NYSE American: OSTX) announced its upcoming participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference taking place Sept. 9-10 in New York City, where OS Animal Health will participate and the company is expected to engage with investors and strategic partners. The conference comes as OS Therapies enters a potentially significant regulatory period for OST-HER2, its investigational therapy for fully resected pulmonary metastatic osteosarcoma. The company expects interim three-year overall survival data and key FDA and U.K. regulatory meetings in September, followed by potential RMAT and Rolling Review decisions, with final three-year data, a U.S. Pre-BLA meeting, and regulatory submissions in the U.S., U.K. and Europe targeted for Q4 2026. OS Animal Health is also seeking USDA alignment on reinstating conditional approval for OST-HER2 in canine osteosarcoma.
To view the full press release, visit https://ibn.fm/ERaOp
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma (“OS”) and other solid tumors. The company is the world leader in gene-edited, listeria-based cancer immunotherapies. OST-HER2, the company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. OST-HER2 has received Orphan Drug Designation (“ODD”), Fast Track Designation (“FTD”) and Rare Pediatric Disease Designation (“RPDD”) from the U.S. Food & Drug Administration and has received ODD, FTD and Advanced Therapy Medicinal Products (“ATMP”) from the European Medicines Agency.
For more information about the company, please visit www.ostherapies.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN